Life Sciences, Healthcare & Pharmaceuticals
Substantial resources are required to finance innovative projects in the life sciences field, frequently requiring young companies to enter strategic agreements with large multinational players. Herzog Fox & Neeman’s Life Sciences, Healthcare & Pharmaceuticals department possesses a unique understanding of all aspects of the business and is the go-to firm for representing businesses in complex collaboration agreements with large global companies.
The department has significant experience working with all relevant parties including: biotech companies, pharmaceutical companies, medical devices and equipment companies, food supplement manufacturers, healthcare providers, medical and research institutions as well as consultants and investors within the industry. The department represents small start-up companies from their inception to exit in either an IPO or M&A transaction, as well as large international pharmaceutical or medical device/equipment companies, advising on all aspects of their commercial, regulatory and transactional activities. Herzog Fox & Neeman's adept corporate skills are coupled with a deep understanding of all the commercial and regulatory aspects of such companies' businesses.
The Life Sciences, Healthcare & Pharmaceuticals department is involved in addressing an extensive variety of agreements such as: founders’ agreements, consultancy, non-disclosure, licence, collaboration, development, joint venture, manufacturing, distribution and M&A agreements, as well as agreements pertaining to obtaining regulatory approvals for manufacturing, marketing and distribution of pharmaceutical and medical devices (e.g., agreements with clinical research organizations, investigators and hospitals) and with various service providers. The department has a unique specialty in representing biotech companies in connection with their collaboration agreements with large pharmaceutical companies.
IP and technology licensing play a key role in Herzog Fox & Neeman’s Life Sciences, Healthcare & Pharmaceuticals department. The department is involved in all areas of intellectual property licensing, with expertise in drafting and negotiating agreements for the research and development, licensing, manufacturing, distribution, sale, branding, marketing, consulting and other forms of commercial exploitation of IP, as well as generating revenue and establishing strategic partnerships. Herzog Fox & Neeman has a unique capability in Israel in advising on Share Purchase Agreements and joint developments/joint ventures with specific IP provisions.
Additionally, the department provides on-going legal services for all major commercial issues specific to the field of pharmaceuticals. This includes handling the legal aspects of the relationship between international pharmaceutical companies and local representatives, in addition to managing the legal issues arising between commercial pharmaceutical companies and healthcare providers. Herzog Fox & Neeman also acts for clients in patent-related litigation and disputes relating to the importation of drugs.
Herzog Fox & Neeman possesses a good working relationship with the Ministry of Health in Israel, including its legal advisor, and various other governmental authorities. The Life Sciences, Healthcare & Pharmaceuticals department regularly represents clients before such regulatory bodies.
Life Sciences, Healthcare & Pharmaceuticals News & Insights
We are delighted to announce that in this year’s BDICode ranking, we are ranked in the top-tier in no less
Herzog is ranked by BDi Code as the top tier in 38 practice areas for 2023
Happy Holidays! Wishing you and your loved ones health and happiness in the new year. May 2023 be an extraordinary
Happy Holidays !
Ofer Sachs, Aviv Barzilay, Dr. Louiza Chitour Ofer Sachs is CEO, Herzog Strategic Ltd. Aviv Barzilay is an Associate at Pitango
New Churidar for the health-techs: a new strategic partnership between Abu Dhabi Department of Health and the Israel Innovation Authority
Our client, Biotech company Immunai inc., closed a major investment from Koch Disruptive Technologies as lead investor and other new
Our client Immunai inc. closed a major investment from Koch Disruptive Technologies as lead investor
We recently represented Pharm Yarok, Rosen High Way, and HW Shinua in their sale to IMC. Pharm Yarok operates a well-known cannabis dispensary in Israel,
Herzog represented Pharm Yarok, Rosen High Way, and HW Shinua in their sale to IMC
Congratulations to Omri, Rotem, and to all of the great team in our digital health client – Medisafe®, on raising $30
Congratulations to our digital health client Medisafe®, on raising $30 million in Series C funding round
Our Client, TelCann LTD, a licensed medical cannabis cultivator, has signed a substantial agreement with Canonic, a company focused on
Our Client TelCann LTD, has signed a substantial agreement with Canonic.
We want to thank you all for tackling the challenges of 2020 with us and hope that in 2021 we
Have a Happy and Healthy New Year 2021
What happens when a doctor thinks it is necessary to recommend an Off-Label use of a drug? What if that
What happens when a doctor thinks it is necessary to recommend an Off-Label use of a drug?
We are excited for our client Cannabotech – The Botanical Pharmacy, which develops innovative medical and pre-medical products based on cannabis
We are excited for our client Cannabotech – The Botanical Pharmacy
As you know, Israel continues its efforts to deal with the Corona Virus and contain it, to avoid its spreading
Handling the Corona Virus- Live Updates
Dan Shalev
Partner
Artificial Intelligence, Cyber & Data Security, Fintech, Crypto & Blockchain, Internet & E-commerce, Privacy & Data Protection, Social & Real Money Gaming, Technology Regulation, Telecom & Media, eCommerce, Media & Adtech
Ron Ben-Menachem
Partner
Capital Markets & Securities, Corporate, Corporate Finance, Mergers & Acquisitions, Telecom & Media